Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Atherosclerosis. 2015 May 16;241(1):176–182. doi: 10.1016/j.atherosclerosis.2015.05.006

Table 5.

Association of Lp-PLA2 levels and risk of incident cardiovascular disease stratified by subclinical disease (n=5456)

Cardiovascular disease
Model 1* Model 2*
Hazard Ratio†
(95% CI)		 p-value Hazard Ratio
(95% CI)		 p-value
Subclinical disease‡, n=3228 (450 events)
  Lp-PLA2 activity 1.17 (1.06, 1.30) 0.002 1.10 (0.97, 1.23) 0.14
  Lp-PLA2 mass 1.17 (1.06, 1.28) 0.001 1.13 (1.03, 1.24) 0.01
No subclinical disease, n=2228 (66 events)
  Lp-PLA2 activity 1.30 (1.01, 1.68) 0.04 1.26 (0.92, 1.72) 0.15
  Lp-PLA2 mass 1.01 (0.78, 1.30) 0.95 0.96 (0.74, 1.24) 0.73
*

Model 1: Adjusted for age, gender and race/ethnicity

Model 2: Model 1 plus BMI, diabetes, smoking status, high school education, systolic blood pressure, use of anti-hypertensive medication, total and HDL cholesterol, use of lipid lowering medications, and CRP.

†

Cox Proportional Hazard ratios expressed per 1 standard deviation increment: 36 nmol/min/mL for activity, 42 ng/mL for mass.

‡

p-value for interaction by subclinical disease status for both Lp-PLA2 activity and Lp-PLA2 mass with the endpoint of CVD are 0.99 and 0.32 respectively.